Citations

Clear

146 citation(s) found for "Simpson, M".

3498 Non-invasive neuromodulation for the treatment of drug-resistant epilepsy: systematic review and meta-analysis investigating efficacy, safety, and optimal stimulation parameters
Premaratne, Sayumi , Hamer, Ryan P. , O’Brien, Terry, Zoghi, Maryam , Antonic‐Baker, Ana , Chen, Zhibin ZC , Chen, Leo , Major, Brendan P. , Thomas, Elizabeth H. X. , Kwan, Patrick , O’Brien, Terry, Lundstrom, Brian N. , Simpson, Hugh D.

Mayo Clinic

Poster Abstracts | October 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: A27.2-A27

10.1136/bmjno-2025-anzan.72 Get It

Identification of key symptoms for a Core Outcome Set for research in vulvar lichen sclerosus: a CORALS symptom domain initiative
Davis, Maya , Li, Amy X , Kottner, Jan , Thomas, Kim S , Simpson, Rosalind , Leclair, Catherine M., Foster, Erin L , Davis, Maya I , Kottner, Jan , Thomas, K S , Simpson, Rosalind , Leclair, Catherine M

Mayo Clinic

British Journal of Dermatology | September 12, 2025 | Volume: 194 | Issue: 2 | Pages: 283-291

10.1093/bjd/ljaf374 | PMID 40982649 Get It

Abstract Background Genital lichen sclerosus (LS) is a chronic inflammatory skin disease that affects men, women and children. It is most common in female patients, with an estimated 1–3% of women affected across their lifetimes. Vulvar LS can cause significant symptoms and affect a person’s quality of life (QoL). To enhance the quality of clinical research and practice, core outcome domains have been identified, including QoL, clinical signs and symptoms, by the Core Outcome Set for Research in Lichen Sclerosus (CORALS) initiative. Objectives To identify key symptoms for the core outcome symptom domain for research in LS. Methods An international multidisciplinary steering committee of experts in vulvar, penile and paediatric LS was convened to define and discuss LS symptoms. A modified eDelphi process was conducted among experts to reach consensus on priority symptoms. An online patient survey was distributed to patient advocacy groups to rank symptoms. A scoping review was performed to identify commonly measured symptoms in LS studies in men, women and children. Results from all three sources were analysed and symptoms selected. Results The patient survey (n = 863) ranked itch, burning, pain, and cuts or tears in the skin as the most important symptoms, with pain with sex being most important to some and least important to others. Ninety-nine per cent of respondents to the survey identified as adult women, limiting generalizability to other populations with LS. Expert consensus identified five key symptoms: itch; pain with vaginal penetration; cuts and tears in the skin; pain; and irritation. The scoping review of 92 manuscripts showed itch, pain with penetration and burning/burning pain as the most frequently measured symptoms. Itch emerged as the most important symptom across all three data sources, with pain also consistently prioritized. Conclusions This study identified five key symptoms for evaluating vulvar LS. Although designed to capture symptoms from all patients with LS, the survey and scoping review both included small populations of male and paediatric participants, highlighting the need for further research in these populations. Based on the results, we suggest measurement of itch, pain, skin cuts and tears, burning and (when relevant) pain with sex within the symptoms core outcome domain for vulvar LS. These findings will be used to inform content validity studies when evaluating potential measurement instruments for the Core Outcome Set.
Metabolomic Evidence of Biological Overlap with Heart Failure with Preserved Ejection Fraction in a Subset of Pulmonary Arterial Hypertension
Reddy, Yogesh N.V. , Asokan, Aneesh K , Hemnes, Anna R. , Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Finet, J. Emanuel , Grünig, Gabriele , Jellis, Christine , Mathai, Stephen C. , Simpson, Catherine E. , Hemnes, Anna , Mathai, Stephen C , Simpson, Catherine E , Nishimura, Rick , Frantz, Robert P. , Hassoun, Paul M. , Barnard, John , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Rosenzweig, Erika B. , Tang, W H Wilson , Nair, K. Sreekumaran , Borlaug, Barry A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 13, 2025 | Volume: 211 | Issue: 9 | Pages: 1701-1713

10.1164/rccm.202501-0034oc | PMID 40504754 Get It

Abstract Rationale A subset of patients with group 1 pulmonary hypertension (PH) have superimposed left heart abnormalities with unclear metabolic implications. Objectives To compare serum/transpulmonary metabolome between group 1 PH stratified by heart failure with preserved ejection fraction (HFpEF) probability. Methods Patients with group 1 PH were stratified into low (<25%) and high (⩾75%) HFpEF-ABA (age, body mass index, and atrial fibrillation) probability, with healthy control subjects and subjects with clinical HFpEF used for comparison of venous and transpulmonary metabolomics. Measurements and Main Results Group 1 PH + high HFpEF probability (n = 131) was associated with a significant increase in 207 metabolites (false discovery rate [FDR] P < 0.05 and fold change >1) (n = 193, t test) and a significant decrease in 231 metabolites (FDR P < 0.05 and fold change <1) (n = 193, t test) compared with group 1 PH + low HFpEF probability (n = 62). Group 1 PH + high HFpEF probability was associated with enhanced tryptophan metabolism with higher downstream kynurenine metabolite concentrations and lower serotonin concentrations (FDR P < 0.002 for all, n = 193, t test). Linoleate (precursor to arachidonic acid and prostaglandins) and arginine and homoarginine (precursors to nitric oxide) were all lower in group 1 PH + high HFpEF probability (FDR P < 0.03 for all, n = 193, t test). Metabolome changes in group 1 PH + high HFpEF probability overlapped with clinical HFpEF (n = 240) but were abnormal relative to control subjects (n = 85) (P < 0.0001 for all, n = 456, t test). There was no evidence of differential transpulmonary uptake/release of most metabolites, suggesting probable nonpulmonary origin (except for serotonin, interaction P = 0.04; and kynurenine, interaction P = 0.03; n = 433, mixed model). Conclusions Patients with group 1 PH + high HFpEF probability have a unique metabolome characterized by enhanced tryptophan-kynurenine pathway breakdown, deficiency of amino acids (such as glycine and serine), lower serotonin, and decreased prostaglandin and nitric oxide precursors. Despite fulfilling clinical criteria for group 1 PH, these metabolome changes were comparable with clinical HFpEF, supporting biological overlap between these two forms of PH.
BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Clinical update and first report of pharmacokinetics (PK) and
Arbour, Kathryn C. , George, Ben , Henry, Jason T. , Leventakos, Konstantinos , Ahnert, Jordi Rodon, Papadopoulos, Kyriakos P. , Perez, Cesar A. , Zuniga, Richard, Wozniak, A., Chin, Curtis D., Mazzei, Antonella , Hu, Zheyi , Simpson, Tyler R., Dickinson, Adam , Jänne, Pasi A. , Ahnert, Jordi Rodon, Johnson, Melissa L. , Spira, Alexander I. , Babiker, Hani M. , Haddox, Candace L. , Chin, Curtis

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3011-3011

10.1200/jco.2025.43.16_suppl.3011 Get It

3011 Background: BMS-986504 selectively binds to the PRMT5-MTA complex, which represents a synthetic lethal target in MTAP -del cancer cells, while sparing MTAP– wild-type cells. In the first-in-human phase 1/2 CA240-0007 study in advanced, unresectable or metastatic solid tumors with homozygous MTAP -del, BMS-986504 was found to be well tolerated and demonstrated antitumor activity in multiple tumors. Here, we report clinical results and the first PK and PD analyses of BMS-986504 from the dose escalation and expansion phases of CA240-0007. Methods: Pts with measurable/evaluable disease and no available treatment (Tx) with curative intent were enrolled; 7 doses were evaluated (50 to 800 mg) in dose escalation. Objective response rate (ORR), disease control rate (DCR), duration of response (DOR), time to response (TTR), safety, PK, PD, including plasma SDMA were assessed. Results: As of 2 Dec 24, 152 heavily pretreated pts were enrolled across all doses: NSCLC (n = 34), PDAC (n = 41), cholangiocarcinoma (n = 12), and mesothelioma (n = 12) were the most common tumor types. With a median f/u of 9.0 mo (95% CI 7.6–9.9), continued durable antitumor activity and deepening tumor regression were seen across tumor types and doses (ORR = 23%, DCR = 70%, median DOR = 10.5 mo, TTR = 4.6 mo). No new safety signals were identified. Most Tx-related adverse events (TRAEs) were grade (Gr) 1 or 2; 13% had Gr ≥ 3 TRAEs (Gr 3 = 12%, Gr 4 = < 1%, Gr 5 = 0). Doses from 50 to 600 mg QD were assessed for PK/PD. The AUC (0-24) after multiple doses was approximately dose proportional at 200 to 600 mg, and the terminal t 1/2 after a single dose was approximately 24 h (table). There were dose-dependent reductions in predicted plasma SDMA, with the 400 and 600 mg doses approaching the plateau. Conclusions: With longer f/u, BMS-986504 continued to show increasingly durable antitumor activity. BMS-986504 demonstrated a favorable PK/PD profile, supporting QD dosing at 400 and 600 mg. These results support further investigation of BMS-986504 at 400 and 600 mg QD as a potential first-in-class synthetic lethal Tx option in pts with advanced solid tumors with MTAP -del. Clinical trial information: NCT05245500 . PK and PD. 50 mg QD 100 mg QD 200 mg QD 400 mg QD 600 mg QD PK after multiple doses t max a (min–max), h 2.0 (2.0–4.0)n = 3 2.0 (1.0–2.0)n = 3 2.0 (0.5–6.0)n = 8 2.0 (0.5–4.0)n = 10 2.0 (1.0–6.0)n = 10 C max , b ng/mL 107n = 3 377n = 3 685n = 8 1240n = 10 2110n = 10 AUC (0-24) , b h∙ng/mL 948 n = 3 3060 n = 3 7150 n = 7 11,800n = 10 26,700n = 9 AUC (0-24) , b,c h∙ng/mL/mg 19.0n = 3 30.6n = 3 35.8n = 7 29.5n = 10 44.6n = 9 Terminal t 1/2 after single dose, d h 21.7 n = 1 80.7 n = 1 21.5 n = 14 21.7 n = 14 24.1 n = 1 PD Translational exposure targets (C avgss ), X 0.08 0.21 0.5 1.1 1.7 Predicted plasma SDMA reduction, a % (90% PI) 30.0 (23.2–37.8) 38.8 (27.1–47.5) 48.3 (42.0–53.0) 55.0 (50.7–57.6) 57.4 (54.3–59.0) a Median. b Geometric mean. c Dose-normalized. d Arithmetic mean.
Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease
Rosen, Darin , Kolb, Todd M. , Mathai, Stephen C. , Suresh, Karthik , D’Amico, Rachel, Hsu, Steven , Tedford, Ryan J. , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Farha, Samar , Grünig, Gabriele , Jellis, Christine , Kwon, Deborah , Park, Margaret , Xiao, L, Fessel, Jeffrey , Fu, Yongping , Postow, Lisa, Schmetter, Barry, Sutliff, R, Tian, Xuefei , Joseloff, Elizabeth, Wong, Brenda , Lawler, Laurie, Maron, B, Haythe, Jennifer , Krishnan, Udhay , Payne, David A., Bergman, Geoffrey , Bastert, K, Devereux, Richard B. , Kim, Ju Youn , Lohman, Julia, Racanelli, Alexandra C. , Ricketts, Michelle L., Sobol, Irina , Singh, Harsimran , Weinsaft, Jonathan W. , Mathai, S.C. , Carey, Kyle A. , Damico, Rachel L. , Enobun, Blessing , Sanni, Y, Brock, Heinz, Durst, Louise A., Head, Denise , Foley, Thomas A. , Gochanour, Benjamin R. , Halbach, H, Krowka, Michael J. , Menon, David K. , Park, Gyu Tae , Redfield, Margaret M. , Rohwer, Kristi, Williamson, Eric E. , Vanderpool, R, Yuan, Jason X.‐J. , Lim, C.S., Abidov, Aiden , Erickson, Harold , Cunningham, James M. , Pugh, Meredith E., Robbins, Ivan M. , Beck, Gerald J. , Aldred, Micheala A. , Asosingh, Kewal, Aylor, Joan, Beck, B, Borowski, A, Collart, Clara, Comhair, S.A.A., Drinko, Jeanne K., Finet, J. Emanuel , Flinn, Aisling M. , Geraci, M, Jacob, Miriam , Kanta, Alexandra, Larive, Brett , Lempel, Jason K. , Li, Minghui , MacKrell, J., Neumann, D., Nawabit, R, Odabashian, Jill, Olman, Mitchell A. , Park, M, Radeva, Milena , Renapurkar, R, Sharp, Jacqueline, Sherer, Stefan, WHW, Tang, Thomas, Jason , Wadih, K, Wells, Simon P. , Wilcox, Jane, Yu, S, Rounds, Sharon , Bull, Todd , Cadigan, John B., Rosen, Darin T , Rosenzweig, Erika B , Rischard, Franz P , Frantz, Robert P , Beck, Gerald J , Hill, Nicholas S , Barnard, John , Grunig, Gabriele , Jellis, Christine L , Kwon, Deborah H , Mehra, Reena , Park, Margaret M , Tang, W H Wilson , Hassoun, Paul M , Simpson, Catherine E , Hemnes, Anna , Horn, Evelyn M , Leopold, Jane A , Tedford, Ryan J , Mathai, Stephen C , Hsu, Steven , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , Barnard, John , Mehra, Reena , Tang, W.H. Wilson , Hassoun, Paul M. , Simpson, Catherine E. , Xiao, L, Fu, Y‐P, Gray, Michael P. , Wong, B, Waxman, Aaron B. , Systrom, David M , Brady, David J. , Chung, Wendy K. , Payne, D, Karas, Maria , Lohman, J, Ricketts, M, Balasubramanian, A, Carey, K, Gao, Lei , Halushka, Marc K. , Kass, David A. , Lin, Ting‐Tse , Mukherjee, Monica , Roth, J, Sanni, Y, Weiss, Robert E. , Zimmerman, Stefan L , Behfar, Atta , Borlaug, Barry A. , Brock, H Du, Head, D, Kane, Garvan C. , Sands, T. , Scott, Christopher G. , Terzic, André , Williamson, E, Garcia, Joe G. N. , Lim, C, Desai, Akshay S , Hansen, L, Newman, J, Brittain, Evan L , Cheng, Feixiong , Filippo, F Di, Flinn, A, Hu, Bo , Jaber, Wael A. , Kanta, A, Martín, Maite Velázquez , McCarthy, Kevin , Ramos, J, Wiggins, K, Willard, Belinda B. , Benza, Raymond L. , Fang, James C. , Gomberg‐Maitland, Mardi

Mayo Clinic

Journal of the American Heart Association | May 22, 2025 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/jaha.124.041127 | PMID 40401597 Get It

Background Right ventricular (RV) maladaptation to elevated pulmonary afterload is the primary determinant of outcomes in pulmonary artery (PA) hypertension; however, the pathobiological mechanisms underlying RV decompensation remain poorly understood. Methods We performed global untargeted metabolomics on plasma from 55 patients who underwent gold‐standard RV‐PA coupling measurements using multibeat pressure volume loop assessment in a single‐center cohort and from 1027 patients with coupling surrogate measurements in a larger multicenter cohort, the PVDOMICS (Pulmonary Vascular Disease Phenomics) study. Age and sex‐adjusted linear regression was performed to identify associations between metabolites and coupling metrics. Additionally, we performed a metabolic flux analysis using gene expression data from RV tissue in an independent cohort of 32 patients. Partial least squares–discriminant analysis was used to identify metabolites and reactions characteristic of the decompensated RV. Results RV‐PA coupling was negatively associated with tricarboxylic acid (TCA) cycle intermediate levels. Specifically, plasma α‐ketoglutarate and fumarate were significantly associated with all coupling metrics in both cohorts. Metabolic flux analysis indicated that decompensated RVs exhibited aberrant TCA cycle activity, including reduced acetyl coenzyme A entry and increased lactate elimination, suggesting a shift from the TCA cycle toward glycolysis at the RV tissue level. Conclusions We identify an association between circulating TCA cycle intermediate levels and RV‐PA uncoupling in 2 independent cohorts, and dysregulated TCA cycle metabolism in decompensated PA hypertension RVs, suggesting that aberrant TCA cycle metabolism could represent a hallmark of RV maladaptation in PA hypertension. Further study of this pathway is warranted to develop novel biomarkers of RV function or RV‐targeted therapies.
Addition of Patient-Reported Outcomes Improves Discrimination of Survival Prediction Models in Pulmonary Arterial Hypertension
Balasubramanian, A. , Simpson, C., Hassoun, P.M., Larive, Brett , Rosenzweig, E.B., Hill, Nicholas S. , Erzurum, S.C., Mathai, S.C., Group, PVDOMICS Study, Mathai, Stephen C. , Balasubramanian, Aparna , Mathai, Stephen C , Balasubramanian, Aparna , DuBrock, Hilary M. , Lammi, Matthew R. , Kolb, Todd M. , Hassoun, P.M., Horn, Evelyn M. , Hemnes, Anna R. , Leopold, Jane A. , Rischard, Franz , Frantz, Robert P.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7611-A7611

10.1164/ajrccm.2025.211.abstracts.a7611 Get It

Abstract Rationale: The 7th World Symposium on Pulmonary Hypertension highlighted the importance of patient-reported outcomes in clinical assessment of pulmonary arterial hypertension (PAH). Patient-reported outcomes, such as health-related quality of life (HRQOL), have been associated with morbidity and mortality in PAH, but the added value of HRQOL measures to validated risk prediction models remains unknown. Methods: Adults with RHC-proven PAH from the Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS) Study, a multi-center observational study, were included in this study. The Pulmonary Hypertension Association Registry (PHAR) was used as a validation cohort. HRQOL was measured using the emPHasis-10 score, where higher scores reflect worse HRQOL. Noninvasive risk assessment was measured by REVEAL Lite 2 risk score, categorized into 3-strata. Cox proportional hazard models were used to model survival evaluating the interaction between risk strata and HRQOL scores, adjusting for age, sex, and incident diagnosis. Harrell's C-statistics were calculated to compare discriminative performance. Results: From the PVDOMICS and PHAR cohorts, 265 and 2671 individuals with PAH and complete emPHasis-10 and REVEAL Lite 2 scores were included. Both cohorts had similar demographics, with an average age of 52±13 and 56±16 years, 75% and 72% female, 81% and 75% White, in the PVDOMICS and PHAR cohorts respectively. Over 87% of PVDOMICS were prevalent cases of PAH, while in the PHAR half were incident. Most individuals (62%) in PVDOMICS were REVEAL Lite 2 low risk, with 16% intermediate and 22% high risk; by contrast, in PHAR 33% were low, 29% intermediate, and 38% high risk. REVEAL Lite 2 scores demonstrated weak to moderate correlation with emPHasis-10 scores in both cohorts (PVDOMICS r=0.48 p&lt;0.001; PHAR r=0.33 p&lt;0.001). Notably, the full range of emPHasis-10 scores were observed in the low-risk individuals across both cohorts. In the PVDOMICS adjusted Cox models, higher emPHasis-10 scores predicted poorer survival (p=0.047) particularly among low-risk individuals (interaction versus high-risk group p=0.08). Similar adjusted models in PHAR demonstrated emPHasis-10 to be a confounder (p=0.001) without significant interaction by risk strata (low vs high-risk interaction p=0.94), but the greatest change in median survival time was observed in the low-risk group (Figure 1). Addition of emPHasis-10 to REVEAL Lite 2 scores improved discrimination in predicting survival (PVDOMICS: C-statistic 0.71 vs 0.73; PHAR: C-statistic 0.67 vs 0.69). Conclusions: Across two multicenter cohorts of incident and prevalent PAH, HRQOL as measured by the emPHasis-10 score improved discrimination for survival, particularly among individuals with lower risk scores.
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Wang, Michael , Song, Yuqin, Jurczak, Wojciech, Kahl, Brad S. , Chu, Michael P., Kryachok, Iryna, Fogliatto, Laura, Cheah, Chan Y. , Morawska, Marta , Li, Yufu, Patti, Caterina , Forsyth, Cecily , Lesley, Robin, Ramadan, Safaa, Rule, Simon, Dreyling, Martin , investigators, for the ECHO, Cazap, Nicolás, Foncuberta, María Cecilia, Garate, Gonzalo, Gustavo, Jarchum, Pavlovsky, Miguel Arturo , Riveros, Dardo, Baker, Ross, Butler, Jason, Cannell, Paul , Cheah, Chan, Forsyth, Cecily, Giri, Pratyush, Johnston, Amanda, Lee, Denise , Lee, Hui‐Peng, Mapp, Sally, Roncolato, Fernando , Thant, Aung , Walker, Patricia, Doo, Nicole Wong, Demuynck, Hilde, Offner, Fritz , Hende, Vanessa Van, Vergote, Vibeke, Wu, Ka Lung , Chiattone, Carlos, Azevedo, Sergio de, Fogliatto, Laura, Fonseca, Ana, Hamerschlak, Nelson, Lazaretti, Nicolas, Rocha, Vanderson, Salvino, Marco, Santucci, Rodrigo, Schaan, Mariza, Scheliga, Adriana, Vieira, Garles Miller, Berinstein, Neil, Boutin, Mélina , Chu, Michael, Keating, Mary‐Margaret, Schattner, Ariah, Restrepo, Diego Villa, Cen, Xinan, Du, Xin, Feng, Ru, Gao, Sujun, Huang, Haiwen, Ji, Jie, Jin, Jie, Ke, Xiaoyan, Li, Dengju, Li, Fei, Li, Jianyong, Li, Junmin, Li, Yan, Li, Yufu, Li, Zhenyu, Lin, Li'e, Liu, Tingbo, Lv, Fangfang , Shuang, Yuerong, Sun, Lan, Sun, Xiuhua, Wang, Zhao, Wu, Huijing, Xi, Yaming, Xia, Ruixiang, Xue, Hongwei, Yang, Haiyan, Yi, Shuhua, Zhang, Cheng, Zhang, Huilai, Zhang, Mingzhi, Zhang, Qingyuan, Zhao, Xielan, Zhou, Hui, Hajek, Roman, Jindra, Pavel , Mayer, Jiri, Novak, Jan, Abraham, Julie, Bijou, Fontanet, Bouabdallah, Kamal , Cymbalista, Florence, Guilbert, Sophie, Laribi, Kamel, Rodon, Philippe, Decker, Thomas, Dreger, Peter, Dreyling, Martin, Hess, Georg, Lenz, Georg, Stilgenbauer, Stephan, Tummes, Dirk, Anargyrou, Konstantinos , Dimopoulos, Meletios-Athanassios, Kapsali, Eleni, Kyriakou, Despoina, Panayiotidis, Panayiotis, Pappa, Vasiliki , Stavroyianni, Niki, Cheng, Hoi Ching, Kwong, Yok-Lam, Lee, Harold, Ng, Ting Ying, Wong, Raymond, Borbényi, Zita , Illés, Árpád, Lázár, Zsolt, Nagy, Ágnes , Nagy, Zsolt, Schneider, Tamas, Avivi, Irit, Gurion, Ronit, Horowitz, Netanel, Ronson, Aaron, Arcaini, Luca, Boccomini, Carola, Ghia, Paolo, Luminari, Stefano, Plenteda, Caterina, Santoro, Armando, Zilioli, Vittorio Ruggero, Zinzani, Pier Luigi, Choi, Ilseung , Ennishi, Daisuke , Ichikawa, Satoshi, Ishikawa, Takayuki, Izutsu, Koji, Kato, Koji, Maruyama, Dai, Nagai, Hirokazu, Ota, Shuichi, Saito, Toko, Sakai, Rika, Suzuki, Ritsuro, Uoshima, Nobuhiko , Yano, Takahiro, Yoshida, Isao, Eom, Ki-Seong, Kim, Jin Seok, Kim, Seok Jin, Lee, Jung-Hee, Mun, Yeung Chul, Yoon, Sung Soo , Arreguin, Elsa Veronica Avila, Andrade, Adriana Dominguez, Almaguer, David Gómez, Vera, Maria Silvia Rivas, Anaya, Luis Solís, Berkahn, Leanne, Pemberton, Lucy, Simpson, David, Beltrán, Brady, Quintana, Shirely, Revilla, Jose Carlos, Vargas, Ernesto, Grosicki, Sebastian , Hałka, Janusz , Jedrzejczak, Wieslaw, Knopińska-Posłuszny, Wanda, Krzanowski, Jacek, Lech-Maranda, Ewa, Robak, Tadeusz, Rzepecki, Piotr , Wróbel, Tomasz, Borsaru, Gabriela, Ciuleanu, Tudor Eliade, Danaı̈la, Catalin, Lazaroiu, Mihaela, Alexeeva, Julia, Chistyakov, Valeriy, Manikhas, Georgy, Mikhailova, Natalia, Proydakov, Andrey, Volodicheva, Elena , Voloshin, Sergey, Bastos, Mariana, Cordoba, Raul, Codina, José , Gonzalez, Eva Maria, Marin, Ana, Panizo, Carlos, Rodriguez, Guillermo, Salar, Antonio, Sancho, Juan-Manuel, Velo, Jose A, Chiu, Chang-Fang, Hsiao, Liang-Tsai, Kuo, Ching-Yuan, Lin, Tung-Liang, Lysa, Tamila, Maslyak, Zvenyslava, Nogaieva, Larysa, Polenkov, Sergey, Usenko, Ganna, Agajanian, Richie, Anz, Bertrand, Chaudhry, Arvind, Chiu, Alden , Cultrera, Jennifer, D’Olimpio, James, Dunleavy, Kieron, Fanning, Suzanne, Flinn, Ian, Gabrail, Nashat, Gallinson, David, Goldenberg, Alec, Graf, Solomon, Grover, N., Hess, Brian, Hoffman, Marc, Isufi, Iris, Kahl, Brad, Kambhampati, Suman , Kirkel, Dean, Diaz, Guillermo Lazo, Levy, Moshe, Liu, Delong, Mead, Monica , Paludo, Jonas, Patel, Anjan, Peles, Shachar, Persky, Daniel, Portell, Craig, Rosenthal, Allison, Sano, Dahlia , Smith, Sonali , Smith, Stephen, Spurgeon, Stephen, Tache, Jason, Tsai, Michaela, Veltri, Lauren, Wang, Michael, Yimer, Habte, Bach, Quoc Khanh, Đỗ, Huyền Nga, Luu, Hung Vu, Khoa, Trọng, Phạm, Như Hiệp, Panizo, Carlos , Kriachok, Iryna , Kahl, Brad S , Paludo, Jonas , Cheah, Chan Yoon , Morawska, Marta , Sancho, Juan-Manuel , Forsyth, Cecily , Dreyling, Martin , Belada, David , Song, Yuqin , Paludo, Jonas , Fogliatto, Laura , Zhang, Jingyang , Lesley, Robin, Ramadan, Safaa Mahmoud , Garate, Gonzalo, Riveros, Dardo Alberto, Cannell, Paul , Cochrane, Tara , Giri, Pratyush, Mapp, Sally , Doo, Nicole Wong , Demuynck, H, Hende, Vanessa Van, Vergote, Vibeke K. J. , CHIATTONE, CARLOS SÉRGIO , Farias, João Samuel de Holanda , Fonseca, Ana Rita Da , Rocha, Vanderson , Oliveira, José Salvador Rodrigues de , Scheinberg, Phillip , Scheliga, Adriana , Vieira, Garles Miller Matias , Berinstein, Neil Lorne , Shuang, Yuerong , Hájek, Roman , Mayer, Jiřı́ , Bijou, Fontanet , Cymbalista, Florence, Delwail, Vincent , Genet, Philippe , Dreger, Peter , Heß, Georg , Lenz, Georg , Stilgenbauer, Stephan , Kapsali, Eleni , Katodritou, Eirini , Kyriakou, Despoina S, Panayiotidis, Panayiotis G. , Symeonidis, Argiris , Schneider, Tamas J., Avivi, Irit, Gurion, Ronit , Horowitz, Netanel A. , Arcaini, Luca , Boccomini, Carola , Luminari, Stefano , Santoro, Armando, Zilioli, Vittorio Ruggero , Zinzani, Pier Luigi , Fukushima, Kentaro , Izutsu, Koji , Maruyama, Dai , Tatetsu, Hiro , Kim, Sang‐A , Oh, Sung Yong , Arreguin, Elsa Ávila, Gómez‐Almaguer, David , Issa, Samar , Revilla, Jose C., Vargas, Ernesto, Lech-Maranda, Ewa, Robak, Tadeusz , Borsaru, Gabriela, Ciuleanu, Tudor–Eliade , Danaila, Catalin-Doru , Alexeeva, Julia, Briones, Javier , Salar, Antonio , Yuste, Victor Jimenez, Chen, Chien‐Yuan , Kuo, Ching‐Yuan, Anz, Bertrand, Cultrera, Jennifer L. , D’Olimpio, James, Dunleavy, Kieron , Gabrail, Nashat , Gallinson, David, Goldenberg, Alec S., Goy, Andre Henri , Graf, Solomon A. , Hess, Brian, Kirkel, Dean, Portell, Craig A. , Rosenthal, Allison , Stevens, Don, Veltri, Lauren Westfall , Yimer, Habte, Tran, Thanh Tung

Mayo Clinic

Journal of Clinical Oncology | May 1, 2025 | Volume: 43 | Issue: 20 | Pages: 2276-2284

10.1200/jco-25-00690 | PMID 40311141 Get It

PURPOSE The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely because of toxicity. Acalabrutinib was shown to be efficacious and less toxic than ibrutinib in a head-to-head trial in chronic lymphocytic leukemia and therefore might lead to better outcomes in MCL. METHODS Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine (90 mg/m 2 once daily; days 1 and 2) and rituximab (375 mg/m 2 as a single dose; day 1) followed by rituximab maintenance in responding patients for 2 years. Crossover to acalabrutinib at disease progression was permitted. The primary end point was PFS per the independent review committee; overall response rate and OS were secondary end points. RESULTS In total, 598 patients were randomly assigned, with 299 in each arm. At a median follow-up of 49.8 months using the reverse Kaplan-Meier method, the median PFS was 66.4 months in the acalabrutinib arm and 49.6 months in the placebo arm (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.94]; P = .0160). Benefit was seen across all subgroups, including those with high-risk features. Overall response/complete response rates were 91.0%/66.6% and 88.0%/53.5% in the acalabrutinib and placebo arms, respectively. OS was not significantly different (HR, 0.86 [95% CI, 0.65 to 1.13]; P = .27). Grade 3 or greater adverse events were reported in 88.9% and 88.2% in the acalabrutinib and placebo arms, respectively. CONCLUSION The combination of acalabrutinib with bendamustine-rituximab significantly improved PFS. Clinical benefit of acalabrutinib with bendamustine-rituximab was achieved with manageable toxicity.
Abstract CT079: Pharmacodynamic (PD) and exploratory biomarker (BM) analysis of the PRMT5 inhibitor BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
Simpson, Tyler R., George, Ben , Jänne, Pasi A. , Arbour, Kathryn C. , Leventakos, Konstantinos , Papadopoulos, Kyriakos P. , Perez, Cesar A. , Zuniga, Richard, Qin, Yidi, Chou, Wen-Chi, Olson, Peter , Anderes, Kenna , Wozniak, A., Chin, Curtis D., Henry, Jason T. , Rodon, Jordi , Johnson, Melissa L. , Spira, Alexander I. , Babiker, Hani M. , Haddox, Candace L. , Kumar, Tapsi , Chin, Curtis, Lei, Ming

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: CT079-CT079

10.1158/1538-7445.am2025-ct079 Get It

Abstract Background: Effective treatments (Tx) are needed for MTAP-del cancers (10-15% of all cancers). BMS-986504 (formerly MRTX1719) is a potential first-in-class MTA-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor that selectively binds to the PRMT5-MTA complex, a synthetic lethal target in MTAP-del but not MTAP-wild-type cells. In the first-in-human phase 1/2 CA240-0007 study, BMS-986504 was well tolerated and showed clinical activity in heavily pretreated pts across multiple advanced solid tumors with homozygous MTAP-del. Here, we report results of exploratory PD analyses of PRMT5 inhibition with BMS-986504 in CA240-0007. Methods: Pts with advanced, unresectable or metastatic solid tumors with homozygous MTAP-del received BMS-986504 (50 to 800 mg) in 3-wk cycles. Symmetric dimethylarginine (SDMA) and intron retention are known PD BMs of PRMT5 inhibition. Therefore, PD effects of BMS-986504 were assessed via changes in plasma and tumor SDMA levels (mass spec and IHC), intron retention, and gene expression (RNASeq) based on samples collected at baseline (BL) and cycle 2 day 1 (C2D1). Additional analyses correlating efficacy outcomes with PD results and select mutations at BL were performed in clinically evaluable pts as of 19-SEP-24. Results: Robust PD modulation of the PRMT5 pathway was observed with BMS-986504. Among pts with matched samples (n = 63), median plasma SDMA levels were reduced by 56% from BL (122.6 ng/mL) to C2D1 (53.8 ng/mL). There were dose-dependent reductions in median plasma SDMA with the greatest reductions at 400 mg QD (59.7% [n = 20]), 400 mg BID (61.9% [n = 9]) and 600 mg QD (59.1% [n = 14]). These PD effects were corroborated in the tumor. Median tumor SDMA levels decreased from an HScore of 285 at BL to 0 at C2D1. Consistent with the SDMA decreases, increased intron retention was observed in 9/11 pts with matched samples. BMS-986504 led to downregulation of several gene pathways including DNA repair and mitotic spindle formation, and MYC and E2F targets, as assessed by RNASeq. There was no significant change in expression of MAT2A, PRMT5, or other PRMT genes, suggesting a lack of compensation for PRMT5 inhibition through these genes. Responses were observed with BMS-986504 across EGFR, KRAS, and TP53 mutation subgroups. Additional correlative analyses among BMs and efficacy outcomes will be presented. Conclusions: BMS-986504 demonstrated robust PD effects across multiple doses and solid tumors which is consistent with the proposed mechanism of action. There was a trend of increasing plasma SDMA reduction across doses, with the greatest reductions observed at 400 mg QD and above. Together these results support further investigation of BMS-986504 at 400 mg QD and higher doses as a potential first-in-class synthetic lethal Tx option in pts with advanced solid tumors with MTAP-del. Citation Format: Jordi Rodón, Tyler Simpson, Ben George, Pasi A. Jänne, Kathryn C. Arbour, Konstantinos Leventakos, Kyriakos P. Papadopoulos, Melissa L. Johnson, Alexander I. Spira, Cesar A. Perez, Hani M. Babiker, Richard Zuniga, Candace L. Haddox, Tapsi Kumar, Yidi Qin, Wen-Chi Chou, Peter Olson, Kenna Anderes, Alice Wozniak, Curtis Chin, Ming Lei, Jason T. Henry. Pharmacodynamic (PD) and exploratory biomarker (BM) analysis of the PRMT5 inhibitor BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT079.
Neurohospitalist Core Competencies
Wold, Jana , Robertson, Jetter , Jeevarajan, Jerome , Knox, Molly G., Thatikunta, Prateek , Solorzano, Guillermo E., Galetta, Kristin , Dujari, Shefali , Goyal, Tarini , Ehrlich, Matthew , Donnelly, J., Marriott, Elizabeth , Mandge, Vishal , Dhoot, Roshni , Luedke, Matthew W. , Maas, Matthew B., Yu, Mei , Tolédano, Michel B. , Palaganas, Jamie L., Kvam, Kathryn A. , Dugue, Rachelle , Meltzer, Ethan , Touma, Lahoud , Shah, Maulik , Douglas, Vanja C. , Orjuela, Karen , Klein, Joshua P. , Likosky, David, Simpson, Jennifer , Richie, Megan , Dohle, Carolin, Morris, Jane G. , Gold, Carl A. , Maas, Matthew B. , Wold, Jana J , Ehrlich, Matthew E , Mustafa, Rafid , Kvam, Kathryn , Meltzer, Ethan , Shah, Maulik P , Orjuela, Karen , Klein, Joshua P , Gold, Carl A , Yu, Margaret Y., Toledano, Michel, Mustafa, Rafid , Palaganas, Jamie, Scott, Brian J.

Mayo Clinic

The Neurohospitalist | November 26, 2024 | Volume: 15 | Issue: 1 | Pages: 13-84

10.1177/19418744241297187 | PMID 39610897 Get It

The Neurohospitalist Core Competencies comprise a set of competency-based learning objectives that encapsulate the knowledge, skills, and attitudes of neurohospitalitists who specialize in the care of hospitalized patients with neurologic conditions. These competencies serve to characterize the rapidly expanding field of neurohospitalist medicine. The 27 chapters are divided into 3 sections entitled: neurological conditions, clinical interventions and interpretation of ancillary studies, and neurohospitalist role in the healthcare system. Each individual learning objective in the chapters describes a specific concept with an action verb to illustrate the behavior that the neurohospitalist exhibits. The individual neurohospitalist may not exhibit mastery in each of the topics included as individual practices vary in scope and practice pattern. A few examples of how the complete set of competencies may be used include in the creation of curricula for neurohospitalist fellowships, to assist in defining the scope of practice of neurohospitalists for administrative leaders of hospitals and departments, and in influencing the direction of further research and quality improvement in the field.